Manufacturing

How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?
Research & Development How Will Lonza-Vertex Deal Transform Gene Therapy for SCD and Thalassemia?

The long-term commercial supply agreement between Lonza and Vertex Pharmaceuticals marks a pivotal moment in the field of gene therapy, promising significant advancements for patients suffering from sickle cell disease (SCD) and beta-thalassemia. This collaboration focuses on the production of

How Did KBI Biopharma Resolve a Pink Media Crisis in GMP Production?
Management & Regulatory How Did KBI Biopharma Resolve a Pink Media Crisis in GMP Production?

KBI Biopharma, a prominent contract development and manufacturing organization (CDMO), encountered a critical issue during a GMP (Good Manufacturing Practice) production run. An unexpected pink discoloration appeared in the cell culture media, a crucial component for biologic drug production. The

Can Ireland Become a Global Leader in Biopharmaceutical Innovation?
Management & Regulatory Can Ireland Become a Global Leader in Biopharmaceutical Innovation?

Ireland has long established itself as a significant player in the global biopharmaceutical industry, boasting a thriving ecosystem supported by robust regulatory and governmental frameworks. With the recent appointment of Shane Ryan as the new president of the Irish Pharmaceutical Healthcare

Theratechnologies Faces Supply Issues for HIV Drug Due to Facility Shutdown
Management & Regulatory Theratechnologies Faces Supply Issues for HIV Drug Due to Facility Shutdown

Theratechnologies, a Quebec-based biopharmaceutical company, is currently navigating challenging waters as it faces potential disruptions in the supply of its crucial HIV medication, Egrifta SV. This drug is widely used to reduce excess abdominal fat in HIV patients suffering from lipodystrophy.

Eli Lilly Expands Irish Facilities to Boost Global Drug Production
Management & Regulatory Eli Lilly Expands Irish Facilities to Boost Global Drug Production

Eli Lilly has announced substantial investments to expand its manufacturing capabilities in Ireland, with over $1 billion allocated to its Limerick facility and $800 million to its site in Kinsale. These expansions aim to significantly boost production capacities for essential biologic active

How Will Richter BioLogics' New Facility Transform Biopharmaceuticals?
Management & Regulatory How Will Richter BioLogics' New Facility Transform Biopharmaceuticals?

The launch of Richter BioLogics' state-of-the-art biopharmaceutical Current Good Manufacturing Practice (cGMP) facility in Bovenau, Germany marks a significant milestone for the company and the industry at large. Positioned as a forefront leader in advanced biopharmaceutical production, the new

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later